PTGER4 and triple-negative breast carcinoma: In addition, upregulated PGE2 receptor EP4 was found in COX2-expressing triple-negative breast cancer, whereas targeting EP4 was suggested to benefit the therapeutic effect of PD-L1 inhibitors [44].